Skip to content
PeptideSport
MyFastRx logo

Provider review

MyFastRx review

The $99/mo advertised rate requires a 12-month prepay — standard rate is $169/mo

MyFastRx is LegitScript certified and prices all doses the same, so cost doesn't escalate as a patient titrates up. Compounded semaglutide runs $169/month standard, dropping to $99/month on a 12-month prepay; tirzepatide follows the same structure at $249/month standard, down to $149/month on 12 months. A SAVE70 first-month promo lowers the trial barrier further. But states served aren't disclosed beyond "multiple states," the corporate address and medical director aren't published, and the pharmacy partner is described only as "state-licensed pharmacies," not named.

Verified August 2026

Straight talk: how we earn — some, not all, of these are affiliate links; start a program through one and we may earn a commission at no extra cost to you. Straight about the rest, too: the write-ups say what each provider is actually worth, and a commission does not change a word of them. Full disclosure here.

On this page

The verdict

MyFastRx is a cash-pay compounded-GLP-1 platform built around fast approval and discounted multi-month bundles. Compounded semaglutide is $169/month standard, dropping to $99/month on a 12-month prepay; tirzepatide is $249/month standard, down to $149/month on 12 months — all doses priced the same regardless of titration, with a SAVE70 first-month promo on top. It's LegitScript-certified and HIPAA-compliant, ships nationwide, and accepts no insurance. States served aren't disclosed beyond "multiple states" or "licensed U.S. providers," the corporate address and medical director aren't published, and the pharmacy partner is described only as "state-licensed pharmacies," not named.

MyFastRx is not ranked on any of our boards. This is a standalone read of what the company publishes about itself — the providers we do rank in this category are on our semaglutide provider ranking. Nothing on this page is a performance claim — see the evidence review for what these compounds do and do not do.

Who it is for, and who it is not

A good fit if

  • You're comfortable with a 12-month prepay to reach the lowest advertised rates
  • You want flat pricing that doesn't rise as your dose increases
  • You want a verifiable LegitScript certification

Look elsewhere if

  • You want the $99/mo headline to be the standing rate — it requires a 12-month prepay; standard is $169/mo
  • You want a published state list, corporate address, or named medical director
  • You want the pharmacy partner named, not just described as "state-licensed"

What it actually costs

What they advertise

Compounded semaglutide "$99/mo" on a 12-month prepay (standard "$169/mo"); tirzepatide "$149/mo" on 12 months (standard "$249/mo"), per myfastrx.com.

What you actually pay, month to month

The $99/$149 figures require a 12-month prepay; the standing month-to-month rate is $169/mo (semaglutide) and $249/mo (tirzepatide).

The commitment trap

The advertised $99/mo headline requires a 12-month prepay; the standard rate without that commitment is $169/mo, 71% higher.

Checked live on MyFastRx's own site at https://www.myfastrx.com/ in August 2026. Prices change without notice — confirm before you buy. Work out what a vial actually gives you with our peptide dose calculator.

What is included

The cheapest headline number in this category is often the one with the least attached to it. Here is what MyFastRx bundles in, and what it does not.

Clinician consult

Not addressed with specific inclusion terms in the sources read.

Bloodwork / labs

Not addressed in the sources read.

Follow-ups and dose changes

Not addressed with a specific cadence in the sources read.

Human support

Not itemized in the sources read.

Injection supplies

Not itemized in the sources read.

Shipping

Ships nationwide, per the homepage.

Pharmacy, labs and oversight

The pharmacy

Not named. Described only as "state-licensed pharmacies," generic.

Oversight

Not addressed with specific inclusion terms in the sources read. Not addressed with a specific cadence in the sources read.

Compounded peptides are not FDA-approved products, and a 503A pharmacy compounds for a named patient while a 503B outsourcing facility manufactures in batches under CGMP. Neither is a quality guarantee on its own — a named facility is simply a fact you can check, and an unnamed “partner pharmacy network” is not. Our guide to verifying a certificate of analysis covers what to ask for.

Where you can get it

Not published — described only as "multiple states" / "licensed U.S. providers."

The honest cons

The part they would rather you skipped

The $99/mo headline is real, but only with a full 12-month prepay commitment; a reader who wants month-to-month flexibility pays $169/mo instead, 71% more than the number that draws them in.

  • Lowest advertised rate ($99/mo) requires a 12-month prepay; standard is $169/mo
  • Corporate address and medical director not published
  • Pharmacy partner not named
  • Cash-pay only — no insurance billing

None of this is unique to MyFastRx — the whole category shares it. What we hold against a provider is the part it hides, and the ways vendors hide things are catalogued in our vendor red-flags guide.

How it compares

Read this before you buy

A provider comparison is half the decision. The other half is whether the compound does anything for you at all — and whether it is allowed where you compete. Growth-hormone secretagogues are banned in tested sport, year-round, and a prescription does not change that.

Facts on this page reflect MyFastRx's own public disclosures when we last checked them, in August 2026. Prices and terms change without notice — confirm on MyFastRx's site before you buy. Provider names and logos on this page identify the company under review; their use does not imply endorsement, sponsorship or affiliation. This page is informational and not medical advice; compounded peptides are not FDA-approved, and growth-hormone secretagogues are banned in tested sport year-round. See our disclosure and editorial policy.